id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-D-4380-0002,FDA,FDA-2015-D-4380,"Best Practices for Communication Between IND Sponsors and FDA
During Drug Development Guidance for Industry and Review Staff",Other,Guidance,2015-12-09T05:00:00Z,2015,12,2015-12-09T05:00:00Z,,2024-11-11T21:14:15Z,,1,0,0900006481d92cbe
FDA-2015-D-4380-0001,FDA,FDA-2015-D-4380,"Best Practices for Communication Between Investigational New Drug
Sponsors and Food and Drug Administration During Drug Development; Draft Guidance for Industry and Review Staff; Availability",Notice,Notice of Availability,2015-12-09T05:00:00Z,2015,12,2015-12-09T05:00:00Z,2016-02-09T04:59:59Z,2016-02-08T22:00:59Z,2015-30931,0,0,0900006481d9267b